AIA
CRMD icon

Alera Investment Advisors’s CorMedix CRMD Stock Holding History

Alera Investment Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-300
Closed -$3K – 286
2019
Q1 		$3K Hold
300
– – ﹤0.01% 724
2018
Q4 		$2K Buy
+300
New +$2.01K ﹤0.01% 740

Other funds holding CRMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SC
Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

Alera Investment Advisors's CRMD Position: Q2 2019 in Review

Alera Investment Advisors sold out of CorMedix (CRMD) in Q2 2019, closing a stake of 300 shares — an estimated $3K sold.

Alera Investment Advisors first reported a position in CRMD in Q4 2018 and held it in 2 quarters. The position peaked at $3K in Q1 2019. 47 funds tracked by Wall St. Rank hold CRMD as of Q2 2019.

  • Alera Investment Advisors reported no remaining CorMedix position as of Q2 2019 after selling out during the quarter.
  • Alera Investment Advisors sold 300 CorMedix shares in Q2 2019, an estimated $3K.
  • Alera Investment Advisors first reported a position in CorMedix in Q4 2018 and held it in 2 quarters.
  • Alera Investment Advisors's CorMedix position peaked at $3K in Q1 2019.
  • 47 funds tracked by Wall St. Rank held CorMedix as of Q2 2019.

Based on Alera Investment Advisors's 13F filing for Q2 2019, filed 7 Aug 2019.